Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec
Executive Summary
Fallout from GlaxoSmithKline's handling of Paxil pediatric studies may lead to increased pressure by Congress or FDA for greater disclosure, Schering-Plough Senior VP-Global Compliance & Business Practices Brenton Saunders said
You may also be interested in...
GSK Paxil CR Ad Medicalizes “Ordinary” Anxiety, FDA Says
GlaxoSmithKline Paxil CR TV ads suggest the antidepressant is appropriate for treating anxiety that does not require medication, FDA's ad division says
GSK Paxil CR Ad Medicalizes “Ordinary” Anxiety, FDA Says
GlaxoSmithKline Paxil CR TV ads suggest the antidepressant is appropriate for treating anxiety that does not require medication, FDA's ad division says
DoJ Launching “Pharmaceutical Fraud Initiative” Ahead Of Medicare Rx
The Department of Justice is launching a "pharmaceutical fraud initiative" to coordinate and increase investigative resources ahead of the Medicare drug benefit's implementation, DoJ Criminal Division Fraud Section Deputy Chief Karen Morrissette said